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Abstract 
Model Driven Optimization of Drug Delivery for Spinal Cord Injury 
Neil Mittal, MD 
Advisor: Yinghui Zhong, Ph.D 
 
 
Spinal cord injuries have an annual new case incidence in the United States of up to 40 
cases per million population, with a 36.2% 10 year survival rate in patients over 50 years 
old.  Barely half of survivors from 40 to 60 can perform activities of daily living, 
regardless of the severity of the initial injury. [1]  Spinal cord injury is progressive, 
mediated by secondary injury, or a subacute inflammatory process that is poorly 
understood. [2-4]  Secondary injury can involve or lead to apoptosis, scarring, cavitation, 
ischemia, and demyelination, among other sequelae, and many of these are not conducive 
to neuronal recovery. [4]  Therefore there is a need for improved ways of addressing 
secondary injury mechanisms in these patients. [2] 
Minocycline can target multiple secondary injury mechanisms through its anti-
inflammatory, anti-oxidative, and anti-apoptotic effects. [5-7]  However, it is only fully 
effective at high concentrations. At the systemic levels required for this, minocycline can 
cause liver toxicity and even death. [8]  Minocycline can form self-assembling, water 
insoluble particles with dextran sulfate and divalent metal cations, with high entrapment 
efficiency and a stable, slow release.  There is potential for a controllable vehicle for drug 
delivery to optimize dosing with minocycline. [8] 
Predicting minocycline release behavior of a complex system can be performed by the 
creation of a model to simplify the system to an equation.  This simplification can be 
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guided by a combination of theoretical frameworks and previous empirical data that 
suggests idealized ratios between the components; previous work suggests the highest 
entrapment efficiency given a 1.2:1 mass concentration ratio of dextran 
sulfate:minocycline, in the presence of 7.2 mM Mg
2+
, suggesting saturation of binding 
sites at these values. [8]  With a high degree of accuracy, this model can help direct the 
optimization of the drug delivery system.  In the case of minocycline:dextran 
sulfate:Mg
2+
, the model proposed in this study was able to predict the trend of behavior 
but not with enough sensitivity for small dosing changes that characterize this delivery 
method.  
Biomedical engineering is an interdisciplinary field that combines understanding of 
various scientific and design expertise.  In order to tailor a drug delivery system, as well 
as help to characterize the mechanism of release, generating a simple model can provide 
insight to the behavior of the system while reducing time, labor, and cost. 
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Introduction 
Problem Background 
Spinal Cord Injury 
Spinal cord injuries (SCI) occur with an estimated incidence of 12,000 new cases 
annually in the United States.  The median age of occurrence is 36.9 years old as of 2010, 
with a higher male incidence, though increased survival results in a greater female 
prevalence.  There is a lower incidence outside of the United States that is attributed to 
lower survival rates of causational events.  Survival of the spinal insult has been shown to 
decrease over time after injury. [1] 
 The most common cause of traumatic spinal cord injuries (TSCI) is reported to be 
motor vehicle collision (MVC), causing 48.3% of TSCI cases.  For the over 60 year old 
population, falls are the leading cause.  The 10 year survival rate patients injured at age 
50 is 36.2%, but only 56.2% of patients between the ages of 40 and 60 can perform their 
activities of daily living (ADL) for functional independence, regardless of injury severity.  
This percentage decreases with age. [1]  There has been little change in survival rate 
since the year 2000 for cervical spinal injury.  The population of SCI survivors included 
48% cervical injury, a number that has remained stable due to the high mortality of these 
injuries. [1] 
 In the Major Trauma Outcomes Study, performed in North America from 1982-
1989, MVC was also shown as the most common cause of TSCI and a high predilection 
for cervical injury (over 50% in all cases, up to 65% in cases of isolated injury).  Of all 
trauma patients admitted, 2.6% had TSCI, and of these there was an average 17% 
mortality across all TSCI cases. [9]  SCI is characterized not only by the initial insult, but 
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also by an evolving, subacute, progressive secondary injury that is well documented but 
still poorly understood. [2-4] 
 SCI therefore carries a high risk of a loss of functional independence, with 
profound effects on mobility, sensation, and the health of innervated tissues.  SCI can 
cause chronic pain, paresthesias, and disability. [10] 
 
Secondary Injury 
Secondary injury is a progressive state of chronic tissue damage that persists after the 
initial injury.  It can be much larger than the acute phase injury, with broader effects (see 
Figure 1). [10]  Secondary injury is caused by hemorrhage, oxidative stress, glutamate 
toxicity, and excitotoxicity. [10]  Secondary injury progression can take a variety of 
forms including apoptosis, scar formation, cavitation or cyst formation, demyelination, 
energy failure, inflammation, local toxicity or excitotoxicity, ischemia, reperfusion 
injury, and oxidative stresses. [4, 10] 
 The major inducers of secondary injury are instigated by the initial insult and 
inflammatory processes. [10]  It directly causes apoptosis, demyelination, and tissue loss 
or cavitation.  Treatment is not reliable, and the remaining tissue mass correlates to 
remaining functionality. [10] 
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Figure 1: Secondary injury, in red, progresses beyond initial tissue insult, in orange  
Z. Wang, et al. "Local delivery of minocycline from metal ion-assisted self-assembled complexes promotes 
neuroprotection and functional recovery after spinal cord injury", Biomaterials, vol. 112, pp. 62-71, 2017. 
 
 
 Secondary injury can progress beyond the initial tissue insult (see Figure 1), and 
has been shown to result in the formation of cysts and progressive cavitary lesions. [3]  
This progression follows the inflammatory response that is a consequence of traumatic 
injury; post traumatic cavitation is preventable but dangerous and clinically significant as 
a sequela of TSCI in up to 3% of cases regardless of severity of the initial injury. [2, 3]  
Therapeutic approaches are few and non-standardized, with surgical and shunting 
methods being the most favorable which suggests the need for new ways to prevent the 
formation of cavitary lesions and cysts in patients of TSCI. [2]  Previous work suggests 
that treating secondary injury is critical, and that chronic neuroinflammation can be 
managed by minocycline therapy, though intrathecal penetration from systemic delivery 
is problematically low. [8] 
 
 
 
 
 
14 
  Neil Mittal 
Intervention Background 
Minocycline 
Minocycline is the only drug that treats the secondary injury in SCI, and does so by 
addressing most of the major causes. [10]  It is a tetracycline antibiotic that has currently 
not fully understood anti-inflammatory behavior.  It exhibits neuroprotection after SCI, 
improves functional recovery, and reduces progressive tissue loss, through it anti-
inflammatory, anti-oxidative, and anti-apoptotic properties. [5-7, 10] 
In mice, it has been shown to reduce tissue damage and extent of loss and 
improve the return of strength and function of the impaired bodily regions with 
histological studies showing preservation of nerve tracts that correlated with higher 
behavioral scores on the Basso Beattie Bresnahan locomotor scale.  This improvement 
was observed as early as 3 days after injury when compared to a control group, and the 
improvement continued while the untreated mice reached a plateau in their recovery.  
Even more clinically important, the minocycline treatment group outperformed a test 
group receiving the current leading conservative therapy, methyl prednisone. [5] 
Minocycline has been evaluated for treatment of noninfectious inflammatory 
disease in humans, such as treatment resistant rheumatoid arthritis.  It has a high 
penetration throughout the body, outside of the central nervous system, and even when 
used predominantly as an antibiotic it was suspected to have utility in treatment of cystic 
fibrosis.  Relevant observations were attributed to an effect of minocycline that is unique 
within its drug class: inhibition of leukocyte migration. [6]  Minocycline reduces tissue 
loss, with better outcomes than the current best conservative therapy, methyl prednisone. 
[10] 
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Currently the mechanism of minocycline neurological anti-inflammation has 
numerous approaches.  It inhibits microglial activation, obstructs the mitochondrial 
calcium overload that triggers apoptosis and upregulates anti-apoptotic factors, and 
minocycline controls reactive oxides and the effect of free radicals. [7, 10]  
In humans, 1-5 days of treatment has been shown to be sufficient for 
neuroprotection in SCI and reduce secondary injury at local doses of 35-75 µg/mL.  A 
recent Phase II clinical trial tested doses of 12-22.5 mg/kg/day (the standard human dose 
is 3 mg/kg/day), and observed poor intrathecal penetration with a local dose of only 2.3 
µg/mL.  This trial also uncovered signs of hepatocellular toxicity in a patient at this 
dosage, in the form of elevated liver enzymes. [10] 
 The minimally effective dose for anti-inflammatory effects alone is 0.5 µg/mL, 
but the neuroprotective dosage is much higher, as mentioned.  1.5-50 µg/mL prevent 
mitochondrial cell death pathways and glutamate toxicity.  10-40 µg/mL prevent 
hemorrhage induced toxicity.  35-75 µg/mL prevent excitotoxicity and Ca
2+
 influx. [10]  
Minocycline also suppresses release of cytokines which may disrupt the blood 
brain barrier.  In different models, minocycline had potential to help treat the progression 
of the following diseases: Parkinson’s Disease, Huntington’s Disease, Alzheimer 
Dementia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Stroke.  All of these 
diseases are characterized by progression, changes in cell count and myelination, and 
micro-infarct and inflammatory processes.  Minocycline suppressed t-cell proliferation in 
experimental models of autoimmune encephalomyelitis. [7, 8]  
Systemic treatment with minocycline in humans, at the high doses needed for 
central nervous system (CNS) penetration has been associated with a myriad of side 
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effects, even in conventional use.  Most concerning, vestibular effects have been found in 
up to 70% of female study subjects.  Other side effects include nausea, vomiting, 
weakness, loss of concentration, headache, visual problems, skin rashes, and tinnitus. 
[11] 
For these reasons, a local delivery system has great therapeutic potential.  One 
approach is to load minocycline in stable, slow release particles, and delivery a particle 
loaded hydrogel reservoir to the injury site, such as shown in the diagram in Figure 1. 
 
Dextran Sulfate and Metal Cations 
Therefore, there is potential in a localized, controllable drug delivery system that can give 
small doses of minocycline to target tissues that would allow for therapeutic treatment 
levels where needed, but keep systemic dosing well below that which may have adverse 
effects.  Polysaccharides are currently viewed as a promising vehicle for nanoscale drug 
delivery and are becoming more widely studied as such.  They can be crosslinked 
covalently or ionically, can form polyelectrolyte complexes from electrostatic 
interactions, and can form self-assembled structures due to hydrophilic and hydrophobic 
interactions. [8, 12] 
Ionic crosslinking of polysaccharides is a fast, low cost, and efficient method of 
forming polysaccharide matrices for drug loading, while covalent crosslinking is more 
expensive, slower, and requires more extreme lab conditions to perform. [12]  Different 
methods can be combined to further tune a drug carrier.  The polysaccharide dextran 
sulfate is a biocompatible polymer that has been shown to have a high binding affinity for 
divalent metal cations, which allow it to bind to minocycline. [8]  It can form ionically 
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crosslinked matrices in the presence of cations and minocycline, with minocycline acting 
as the inducer and linker. [8, 12]  In Figure 2, red boxes represent metal ion chelation sites 
and the blue box represents the site of direct DS – MH interaction. [8] 
This particle loading can provide time and dose control over drug delivery. [10] 
 
 
 
Figure 2: Schematic from previous work for particle formation  
Z. Zhang, et al. "Metal ion-assisted self-assembly of complexes for controlled and sustained release of minocycline for 
biomedical applications," Biofabrication, vol. 7, p. 015006, 2015. 
 
 
Hydrogel Loading 
Local delivery requires control over localization of the drug reservoir.  A biocompatible 
hydrogel, such as agarose, can be used to maintain the position of the particles over the 
injury site.  In combination with particlization, hydrogel loading opens the possibility of 
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maintaining a local drug reservoir that can be held in place for a set duration without the 
drug being washed away by bodily fluids. [10] 
 
Mechanism and Need for Model  
Currently the dose that can be delivered from previously studied entrapment methods is 
stable and long lasting, as seen in Figure 3. 
 
 
 
Figure 3: Slow release of minocycline from minocycline-dextran sulfate-Mg
2+
 particles 
Z. Wang, et al. "Local delivery of minocycline from metal ion-assisted self-assembled complexes promotes 
neuroprotection and functional recovery after spinal cord injury", Biomaterials, vol. 112, pp. 62-71, 2017. 
 
 
The combination of minocycline hydrochloride (MH), dextran sulfate (DS), and a 
divalent metal cation, such as magnesium, forms a self-assembling, water insoluble 
complex with a proposed chemical reaction of: 
(1) 𝑀𝐻 + 𝐷𝑆 + 𝑀𝑔2+  
  𝑘𝑓𝑜𝑟/𝑘𝑟𝑒𝑣  
↔        [𝑀𝐻 − 𝐷𝑆 −𝑀𝑔2+] 
This particle formation has very high drug entrapment with a slow and stable release of 
minocycline.  The system overall is pH dependent, as the ionic interactions change with 
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pH, which offers a degree of control for innate dosing changes relative to local 
inflammatory acidosis.  [8] 
Bioactivity analyses and neuroprotection studies have showed efficacy of released 
MH.  The anti-inflammatory minimal effective local dose of 0.5 µg/mL was not high 
enough for neuroprotection, but further studies aim to better control this release. [8]  
 Current understanding of this mechanism requires further evaluation, but some 
details have been studied.  It requires one charged polymer (DS), forms an insoluble 
complex, and requires all 3 components to form.  FTIR has suggested that the sulfate and 
hydroxyl groups on DS react with MH, the sulfate group also can bind the cation, and 
there is a chelation site for cation binding on MH (C10-C12).  MH has a potential second 
metal binding site.  Direct interaction with DS is possible by forming a positively charged 
ammonium group that could directly form an ionic bond to the negative sulfate group on 
DS.  However, no insoluble bonds form between any 2 of these components, despite 
evidence that suggests that any 2 will react. [8] 
 Therefore, a proposed mechanism suggests that crosslinking of DS is needed, and 
one MH molecule can bind to two DS sites through either cation bonding, electrostatic 
interaction, or hydrogen bonding.  At least one of these bonds however must be cation 
bonding, as the other two are not strong enough to maintain a complex.  The peak 
complex occurs at a DS:MH ratio  of 1.2:1 by mass concentration (empirically derived, 
molecular weight of DS is variable), and corresponds to a molar ratio of sulfate:MH of 
3:1, suggesting that higher or lower concentrations of DS to MH leave one in excess 
relative to the other.  Increasing the cation concentration does raise MH loading by 
increasing DS binding, but only until some saturation concentration. [8, 10] 
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Thesis Statement 
To better predict the behavior of this drug vehicle, and to better direct further studies, it is 
important to find the relationship between the parameters of vehicle creation and the 
resulting particle characteristics and drug release profiles.  This relationship can be used 
to model the drug release of a given proposed vehicle composition, and therefore be used 
to direct research or even therapeutic development. 
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Design Component 
Overall Problem  
The overall goal for this investigation is to tailor a delivery system for local and 
controlled drug dosing.  Patients with SCI need a sustained and stable injury site 
exposure to minocycline at levels that are systemically toxic, and a chelation particle 
formulation is capable of high levels of entrapment of minocycline with slow release. [8]  
The release of this system varies as the starting concentrations of its constituents are 
changed, but optimization of the delivery has yet to be completed and the mechanism is 
still unclear. 
 Therefore, it is intended for the work of this study to further the understanding of 
the system while also completing its design to deliver a therapeutic dose of minocycline 
for mitigation of secondary injury in SCI. 
 
Specific Problem  
As the drug release can be affected by changes in the initial conditions of all three 
components, there are many conditions that need to be evaluated for any release profile 
or effect characterization. [8]  Due to the complexity and cost of experimentation, as well 
as the time necessary for such studies, there is a need to be able to predict the profile and 
therefore choose the right conditions to test for optimal vehicle characteristics. 
 Since the mechanism of drug entrapment and release is not yet fully described in 
this novel system, it is also important to better understand how the formulation relates to 
its function.  Once again, testing every possible combination of conditions is impractical, 
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and there is need for a method to predict ranges of outcomes and trends of vehicle 
behavior for a chelation based drug delivery system. 
 
Model Design  
Evaluation of the problem and the obstacles in both optimizing a system and 
characterizing a mechanism has shown that there is room for predictive modeling in drug 
delivery investigations.  Discussions with drug development labs both in academia and 
industry have shown that there is a broad interest in simple approaches to modeling drug 
release, where a lack of expertise for modeling complex systems is the large obstacle to 
implementation of modeling processes in current approaches, as confirmed in an 
interview conducted October, 2016, with Boris Polyak, PhD, Assistant Professor of 
Surgery at Drexel University College of Medicine.  
Therefore this investigation of the biomedical engineering skill-set should 
combine the engineering design approach of organizing a system in fundamental sections, 
the scientific principles of evaluating chemical behavior, and the math and computer 
skills needed to render these entities in a usable form.  It is intended that a model of drug 
release behavior can support or reject proposed mechanisms and reduce the number of 
conditions needed to consider for system optimization.  The objective of this design is to 
characterize a chelation particle system as a function of controllable input parameters and 
then apply it to minocycline entrapped with dextran sulfate and magnesium cations. 
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Vehicle Design  
After the generation of a model, this investigation should implement it.  As stated, the 
overall problem is still developing and understanding a method of local drug delivery for 
a specific problem, and the model itself is a means to that end.  The objective of this 
design is to present a system that can release a sustained, controlled dose of a 
minocycline from the chelation particle vehicle. 
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Aims 
Specific Aim 1: Determination of the effect of controllable parameters on 
minocycline. 
There are 3 components to this drug release vehicle within the hydrogel: the drug (MH), 
the polysaccharide residue (DS), and the chelator (Mg
2+
), which at specific 
concentrations results in a system that has high entrapment and very stable release.  Each 
of these components can be manipulated for their initial concentration at the Control level 
as well as a High and Low value. 
 The first aim of this study is then to determine the effect of these parameters on 
the release of MH through a factorial designed experiment.  High entrapment efficiency 
occurs at binding sight saturation which is determined by the initial concentrations of 
components.  Therefore the highest entrapment efficiency condition should represent the 
most stable and lowest dose release. [8, 10]  There are expected to be observable trends 
of release behavior relating to entrapment efficiency and these effects are to be 
characterized.  As there are ratios between the particle constituents that will result in 
different particle stability, and previous work has suggested the most stable form of the 
particle [8], this aim will investigate the behavior of drug release for different initial 
conditions. 
 
 
 
 
25 
  Neil Mittal 
Specific Aim 2: Design of a mathematical model to predict daily release of 
bound minocycline from a hydrogel . 
The second aim of this study is to develop a mathematical model to predict the daily 
release of a drug from a chelation bound particle loaded within a hydrogel source.  This 
includes both a general applicability as well as system specific functionality for the drug 
delivery vehicle being studied. 
The complexity of this system can be evaluated as a combination of more simple 
problems.  Execution of this aim will involve the application of scientific principles to 
derive mathematical representations of system behavior.  This includes the formation of a 
usable form of the model and comparisons between model output and empirical data.  
Ultimately, simplification of the system’s transport processes and quantification of 
constants in control conditions will define the drug release behavior. 
Below are the steps that comprise this aim. 
I. Development of model 
a. Simplify components of system and overall transports process 
b. Quantify constants, assuming the control conditions 
II. Evaluation of model 
a. Verification 
i. Generate field of outputs and compare to empirical data of control 
conditions gathered in Aim 1 
b. Validation 
i. Compare output of model to empirical data for High and Low 
concentration conditions of Aim 1 
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Specific Aim 3: Application of a model to guide optimization of a modifiable 
drug delivery. 
The design of a model is a means to the end of presenting a method of delivering MH at 
desired doses.  Therefore, without application of the model, the overall purpose is not 
met.  Therefore, the third aim is to use the model outputs to increase understanding of the 
mechanism of delivery and propose conditions that can yield unique, discrete, and 
specific drug release results specific to this system. 
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Design Inputs 
See Table 1 for the traceability matrix from design criteria to validation.  The model must 
have a reasonable amount of accuracy, predictive behavior, and usability. 
 
 
Table 1: Traceability matrix for design inputs and outputs 
Constraints # Criteria # Specification # Verification # Validation 
Simplicity 
within 
student 
modeling 
ability 1 
Predict 
release above 
minimally 
relevant dose  
(R
2
 > 0.9; 
p < 0.05) 1 Model 1.1 
Compare 
model 
outputs to 
training data 2.1 
Release 
studies with 
testing data 
Equipment 
within lab 2 
Able to 
predict 
release 
profiles for 
parameter 
combinations 
beyond 
training data       2.2 
Follow-up 
release 
studies 
 3 
Usable 
Interface         3.1 
Usability 
Analysis 
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Model Conceptualization and Formation 
The rate of particle degradation was found in a multistep method.  Using chemical 
simulations of semi-empirical methods through MOPAC software, the system was 
simplified to two parts by way of binding energies: MH and the bound DS-Mg
2+
 vehicle, 
which reduced the chemical reaction to a 2 component reaction with the stability of the 
residue-chelator bond being a function of their initial concentrations: 
(2) 𝑀𝐻 + [𝐷𝑆 −𝑀𝑔2+]  
  𝑘𝑓𝑜𝑟/𝑘𝑟𝑒𝑣  
↔        [𝑀𝐻 − 𝐷𝑆 −𝑀𝑔2+] 
Based on previous work, it was proposed that the most stable condition resulted from a 
ratio of DS:MH concentration of 1.2:1 mg/mL, at 7.2 mM of Mg
2+
.  This 1.2:1 ratio of 
DS:MH concentrations represents the condition with highest entrapment efficiency. [8]  
As per empirical studies, DS release can be estimated to follow zero, first, or some other 
order of reaction.  Using half-life relationships between time to equilibrium and the rate 
constant, rate constants can be estimated empirically, and rate constants can be used in 
calculations to predict particle degradation as functions of time and concentration. 
 Drug release is a function of time, source concentration, sink, and diffusivity of 
drug through medium.  In a general form, resulting from manipulation of Fick’s Laws of 
Diffusion and conservation of mass: 
(3) 
𝑑
𝑑𝑟
(𝑟2𝑁) = 0 
(4) 𝑁 = −𝐷 ∙
𝑑𝑐
𝑑𝑟
 
for N being flux, D representing the diffusion coefficient of the chemical in question 
through the chosen medium, r representing the radial axis from the center point of the 
sphere of hydrogel, and c representing the molar concentration of free drug within the 
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hydrogel.  With assumptions of pseudo-steady state, that the rate of reaction of particle 
formulation and degradation being on a different order than that of diffusion, there is no 
other reaction being considered in the movement of the drug.  It can also be assumed due 
to the dilute drug release into the release media, that there is an infinite sink for diffusion 
purposes. 
 Applying a shell balance, where the amount of mass in a shell is constant at a 
specific point in time, the product of flux and surface area is constant.  For a changing 
concentration over time but stable hydrogel volume, this can be written as: 
(5) 𝑊 = 𝑁 ∙ 𝑆𝐴 = −
𝑉
𝑀
∙
𝑑𝜌
𝑑𝑡
 
for W moles of drug in the shell, SA surface area of the shell, V representing volume of 
the hydrogel bead, M molar mass of the drug, t being time, and ρ meaning mass density 
of the drug.  Manipulation of Equations (3) and (4) result in two equations for W: 
(6) 𝑊 = 4𝜋𝑅𝐷𝑐 =
𝑉
𝑀
∙
𝑑𝜌
𝑑𝑡
 
where R is the radius of the hydrogel bead.  Boundary conditions can be assumed that at 
time t = 0, the density ρ of drug within the hydrogel is ρi, and at time t = ti, ρ = ρtf.  
Integrating and solving for final density yields: 
(7)  𝜌𝑡𝑓 = 𝜌𝑡𝑖 −
4𝜋𝑅𝐷𝑀
𝑉
∙ 𝑡𝑖 ∙ 𝑐𝑖 
The value of c can be calculated at a given moment as a function of the current 
concentration of the particle constituents.  Given Equation (2) above, the change in 
concentration of MH at any point in time can be found by: 
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(8) 
𝑑[𝑀𝐻]
𝑑𝑡
|𝑡𝑖 = 𝑘𝑟𝑒𝑣([𝑀𝐻 − 𝐷𝑆 −𝑀𝑔
2+]0 −
𝛴[𝑀𝐻]𝑡𝑖−1) − 𝑘𝑓𝑜𝑟[𝑀𝐻]𝑡𝑖−1([𝑀𝐻 − 𝐷𝑆 −
𝑀𝑔2+]0 − 𝛴[𝐷𝑆]𝑡𝑖−1) 
This is the rate of generation of MH from degrading particles, given the changing 
concentrations of MH and DS.  DS efflux can be more accurately estimated as a function 
of time based on the order of its kinetics, derived empirically.  The concentration can be 
calculated at each time point iteratively starting from known initial conditions and 
entrapment efficiencies.  A series of functions representing the various portions of this 
formula can then be used to characterize the movement of MH from the particles to the 
release media, with the mathematical representation of the full formula being: 
(9) 𝜌𝑡𝑖 = 𝜌𝑡𝑖−1 −
4𝜋𝑅𝐷𝑀
𝑉
∙ 𝑡𝑖 ∙ {𝑐[𝑀𝐻]𝑖 +
𝑘𝑟𝑒𝑣(𝑐[𝑀𝐻 − 𝐷𝑆 −𝑀𝑔
2+]𝑡𝑖−1 −
𝑐[𝑀𝐻]𝑡𝑖−1) − 𝑘𝑓𝑜𝑟𝑐[𝑀𝐻]𝑡𝑖−1(𝑐[𝑀𝐻 −
𝐷𝑆 −𝑀𝑔2+]𝑡𝑖−1 − 𝑐[𝐷𝑆]𝑡𝑖−1)} 
Note that the bracketed molecules denoted by ‘c’ are in molar concentration, representing 
the state within the hydrogel.  This equation can be separated into components by 
distributing constants and separating the function that represents the generation of MH to 
better represent the movement of MH between the particle, free hydrogel, and media 
compartments.  Assuming that the amount of time between ρti and ρti-1 or the duration of 
ti is 1 second, then the value for ti at each iteration is 1, and the formula can be run 
iteratively to characterize MH movement over time. 
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Methods 
See Appendix for Equipment, Software, and Materials 
Gel Formulation 
Particles were made in situ to ensure even distribution within the hydrogel.  Solutions for 
1.5% agarose hydrogels were prepared with final concentrations as per Table 2, using a 
mixture of double concentration MH in one solution, and double concentration of DS and 
Mg
2+
 prepared in 3% agarose (stored at 80 °C) in another, using deionized water as the 
solvent.  These solutions were combined 1:1 resulting in the desired concentrations for 
all, then pipetted in 20 µL gel volumes, each condition prepared in triplicate. 
All samples were loaded into a 96 well plate for release studies.  Samples were 
maintained at 37 °C in 100 µL of release media, Hanks Buffered Saline Solution (HBSS), 
which is prepared according to lab protocol to mimic the intrathecal environment 
(formulation is listed in the appendix).  Release media was replaced each day at the same 
time for 5 days and the concentrations of MH were measured. 
 
 
Table 2: Initial conditions for drug particle loaded hydrogels 
Condition Minocycline (mg/mL) Dextran sulfate (mg/mL) Magnesium (mM) 
Control 1.0 1.2 7.2 
Low 0.5 0.6 1.8 
High 2.0 2.4 14.4 
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Entrapment Efficiency 
Using the same fabrication approach as the gel preparation, without the agarose, particles 
were made for the concentration conditions of Table 2.  Samples were centrifuged at 
10,000 RPM for 10 minutes to separate particles from solution.  Release for MH was 
taken from each supernatant and the ratio of free MH to total loaded MH was recorded.  
This was done both as part of the investigation for Aim 1, as well as to provide initial 
values of free MH within the hydrogel depending on the conditions used to prepare them. 
 
Release Studies: Minocycline 
At the same time each day for 5 days, MH was measured at 380 nm light using the 
NanoQuant spectrometer, for 40 µL of media.  Absorbances were converted to release 
media drug concentration and released drug mass by a standard curve generated from the 
stock solution. 
 
Model Generation 
After simplifying the system to components, constants were empirically derived.  
Diffusion of MH from the agarose hydrogel was evaluated by loading 20 µL 1.5% 
agarose hydrogels with 1 mg/mL MH and measuring drug release at 5-10 minute 
intervals.  Manipulations of Fick’s law and shell balance, Equations (5) & (6), were used 
to calculate the diffusion coefficient. 
(10) 𝐷 =
𝑉
4𝜋𝑅
𝑑𝜌
𝑑𝑡
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 The half-life of reaction equilibrium was evaluated by forming particles at the 
control concentrations without agarose.  Samples were made for time points of 5-10 
minute intervals.  At its time point, each sample was centrifuged at 10,000 RPM for 10 
minutes to remove particles, and the MH concentration of the supernatant was evaluated.  
Assuming first order kinetics, the rate constant of particle degradation (krev) was 
estimated using the half-life of particle degradation.  The rate of particle formation (kfor) 
was also estimated based on the rapid formation of particles. 
As per empirical data (see Results), DS release follows a half-life time pattern that 
is fairly constant regardless of concentration or time that suggests a first order kinetic 
reaction for particle degradation which has a half-life relationship of: 
(11) 𝑡1/2 =
𝑙𝑛(2)
𝑘𝑟𝑒𝑣
 
The system equilibriates more rapidly than the used measurement methods, while 
diffusion of free drug can be captured by daily release, therefore these occur at rates that 
differ enough to suggest a pseudo-steady state system for drug release to diffuse media 
with regards to free drug generation. [13]  At equilibrium, the equilibrium constant can be 
found, from which the rate constant in the opposite direction can be derived: 
(12) 𝐾𝑒𝑞 =
[𝑀𝐻]∙[𝐷𝑆−𝑀𝑔2+]
[𝑀𝐻−𝐷𝑆−𝑀𝑔2+]
 
(13) 𝐾𝑒𝑞 =
𝑘𝑓𝑜𝑟
𝑘𝑟𝑒𝑣
 
 Using the principles discussed in Model Conceptualization and Formulation 
section, the mathematical model was then derived with these constants. 
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Model Verification and Validation 
The model was written into MATLAB as a function and then used to predict the daily 
release of the control condition over 5 days.  This was compared to the empirical results 
with the corrcoef function, which provides the correlation of coefficients (R
2
) as well as a 
measure of statistical significance.  For validation, to see if the model was applicable 
when the particle stability was altered by changing the initial conditions, the outputs for 
High and Low concentration conditions were then compared to empirical data as well 
using the same method of comparison. 
 The corrcoef function provides correlation and significance analysis for nonlinear 
and noncategorical data, as opposed to a Pearson’s Goodness of Fit, while representing 
trend accuracy as opposed to error sum methods.  The conventional p value of p < 0.05 
was used as the threshold of significance. 
 
System Optimization 
With the presumed successful verification and validation of the model complete, analysis 
of the behavior of the vehicle was to be assessed using statistical comparisons to test for 
significantly different release profiles.  Empirical data was used when model data was not 
sufficient.  In the event of a lack of significant differences in release profiles, or with a 
poor correlation, optimization would be beyond the scope of this study.  Otherwise, 
optimized system parameters would be chosen by model outputs as choosing the initial 
conditions that resulted in the most favorable release profile. 
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Model Usability Analysis 
The final MATLAB function was then evaluated to test for its usability.  Qualitative goals 
were to ensure a limited number of inputs and steps to generate output data. 
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Results 
Empirical Data from Release Studies 
In Table 3 the release results from experimentation are presented for MH.  It can be 
observed that the control condition has the lowest mass release of MH over time, and 
remains largely stable, despite an aggressive burst dose.  High Mg
2+
 and high MH initial 
loading present with larger bursts, and all samples trend towards similar profiles as 
control after the first day.  ANOVA of the release shows that the different conditions do 
have significant differences (p < 0.001).  Not including the highly variable Day 1 release, 
the different conditions still did have statistically significantly different outputs, even if 
there is overlap of their values and a trend towards control condition behavior (p = 
0.0016). 
 
 
Table 3: Daily release of minocycline from particle loaded hydrogels  
 
 
 
Daily releases can be more easily observed in Figure 4 below, which summarizes 
the table. 
 
 
Day Control Low Mg2+ High Mg2+ Low MH High MH High DS
1 3.66 2.03 4.56 2.71 4.77 3.56
2 1.00 0.89 1.26 0.86 1.22 1.10
3 0.96 0.88 1.00 0.86 1.08 0.91
4 0.83 0.80 0.80 0.75 0.94 0.89
5 0.75 0.77 0.79 0.73 0.90 0.83
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Figure 4: Daily observed mass release of minocycline 
 
 
 Entrapment of MH varied by initial conditions and the entrapment efficiencies for 
each are shown in Figure 5. 
 
 
 
Figure 5: Minocycline entrapment by condition 
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 As per semi-empirical simulation for mechanical binding via MOPAC, the 
mechanical binding energies of the different component combinations are -4,791 eV for 
DS-Mg
2+
, -5,494 eV for MH-Mg
2+
, and -10,619 eV for all 3 combined.  MH alone is -
5,814 eV while DS alone is -4,771 eV.  This reveals an energy of binding for MH to DS-
Mg2+ of -15 eV and DS to MH-Mg
2+
 of -354 eV which is less stable.  This suggests that 
DS complexes with Mg
2+
 with significantly more stability than MH does, allowing for 
the treatment of DS and Mg
2+
 to be treated as a subunit for model simplification 
purposes, assuming constant energy of binding. 
 
Diffusion Coefficient Estimation 
Figure 6 shows the plot of the diffusion coefficient (D) in m
2
/s empirically derived by 
point measurements in time (min).  The value plateaus near 2x10
-12
 m
2
/s after the values 
for D stabilize and plateau. 
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Figure 6: Diffusion coefficient of minocycline in 1.5% agarose 
 
 
Rate Constant Estimation 
As shown below in Figure 7, the system reached equilibrium fairly rapidly that showed 
negligible change over time, and the relative concentrations yielded an equilibrium rate 
constant (Keq) of 0.0026 1/s, using an average of the results for time before the initial 
time point.  As a result, with a small magnitude of time assumed for the half-life, the 
particle degradation rate constant (krev) was found to be 0.0145 1/s using a similar 
estimation of time until the midpoint between fabrication and the first time point.  Using 
the relationship between these rate constants, the particle formation rate constant (kfor) 
was found as 0.000038 1/s, many orders of magnitude smaller than the degradation rate 
constant. 
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Figure 7: Equilibrium state: concentration of released supernatant 
 
 
Entrapment Efficiencies 
The entrapment efficiencies of MH for each tested condition were used to create an 
entrapment map as a function of all three variable initial conditions.  As the lowest 
entrapment was still well above 90%, it was assumed that the loss of efficiency was not 
additive and for simplicity was treated as a series of linear relationships.  Between the 
low and control conditions and control and high conditions, individual lines were 
generated, as seen in Table 4.  If multiple conditions were varied, these entrapment 
efficiencies were averaged rather than compounded.  Entrapment Efficiencies were 
calculated as a line function of chosen concentrations of MH and DS in mg/mL, and 
Mg
2+
 in mM. 
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Table 4: Coefficients of line between tested points for entrapment efficiency 
 
 
 
 These lines comprise an entrapment efficiency map that can used to interpolate 
the initial concentration of bound and free drug within the hydrogel upon particle 
formation.  See Figure 8 for map. 
 
 
 
Figure 8: Entrapment Efficiency Map 
 
 
This assumption was challenged, by testing entrapment efficiencies at the 
midpoints of each line, and then 3 random combinations of variable manipulation.  The 
results are shown in Table 5.  It can be observed that the assumption does not actually hold 
Condition Low Mg2+ : Control High Mg2+ : Control Low MH : Control High MH : Control Low DS : Control High DS : Control
Line Slope 0.009 -0.00027 0.001 -0.017 0.061 -0.017
Line Intercept 0.930 0.998 0.979 1.013 0.923 1.017
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consistently so there is some more complexity to the entrapment mechanics.  The 
concentrations used for the components are listed in the table, and the same method was 
applied for particle formation and testing as before. 
 
 
Table 5: Entrapment efficiency linearity assumption challenged 
 
 
 
Model Usable Form and Output 
The final form used for application was the matrix formula of the final equation above, 
Equation (9).  After conversion of mass density to molar concentration, the system takes 
the form of Equation 14 below: 
(14)   
{
𝑐[𝑀𝐻]
𝑡𝑖
𝑐[𝑀𝐻 − 𝐷𝑆 − 𝑀𝑔2+]𝑡𝑖
}
= {
1 −
4𝜋𝑅𝐷𝑀2
𝑉
𝑡𝑖 −𝑘𝑟𝑒𝑣
4𝜋𝑅𝐷𝑀2
𝑉
𝑡𝑖
−
4𝜋𝑅𝐷𝑀2
𝑉
𝑡𝑖 1 − 𝑘𝑟𝑒𝑣
4𝜋𝑅𝐷𝑀2
𝑉
𝑡𝑖
} {
𝑐[𝑀𝐻]
𝑡0
𝑐[𝑀𝐻 − 𝐷𝑆 − 𝑀𝑔2+]𝑡0
} 
 
mM Mg 4.5 10.8 7.2 7.2 7.2 7.2 4.5 10.8 4.5
mg/mL MH 1 1 0.75 1.5 1 1 1.5 0.75 0.75
mg/mL DS 1.2 1.2 1.2 1.2 0.9 1.8 0.6 1.2 1.8
Predicted 
Value 0.971 0.995 0.980 0.988 0.978 0.986 0.973 0.990 0.979
Average 
Measured 
Value 0.911 0.967 0.748 0.912 0.910 0.980 0.566 0.700 0.201
Standard 
Deviation 0.009 0.004 0.005 0.038 0.012 0.002 0.057 0.093 0.043
Percent 
Error 0.06 0.03 0.24 0.08 0.07 0.01 0.42 0.29 0.79
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Output of the predicted daily mass release of MH is shown below in Table 6.  This 
table and Figure 9 below provide the output data for the same test conditions empirically 
evaluated, as generated by the model derived in this experiment.  The subsequent figures 
(Figure 10 - Figure 15) provide graphical comparisons of data output by individual condition 
to empirical data.  Different conditions did have different modeled release profiles, as per 
ANOVA analysis (p = 0.049).  It can be observed that the model captures a genuine 
profile only in some of the cases, though aggressively moves towards a daily release of 
zero in more conditions and without observable pattern, and therefore cannot be said to 
accurately portray daily release. 
 
 
Table 6: Model output of minocycline daily release by mass (µg) 
 
 
 
Day Control Low Mg2+ High Mg2+ Low MH High MH High DS
1 0.06 4.13 0.21 0.70 2.90 1.68
2 0.00 2.30 0.00 0.23 0.99 0.65
3 0.00 1.63 0.00 0.06 0.29 0.27
4 0.00 1.08 0.00 0.00 0.00 0.00
5 0.00 0.64 0.00 0.00 0.00 0.00
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Figure 9: Daily predicted mass release of minocycline 
 
 
 
 
 
Figure 10: Modeled and empirical data for Control condition 
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Figure 11: Modeled and empirical data for Low Mg
2+
 condition 
 
 
 
 
 
Figure 12: Modeled and empirical data for Low Mg
2+
 condition 
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Figure 13: Modeled and empirical data for Low MH condition 
 
 
 
 
 
Figure 14: Modeled and empirical data for High MH condition 
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Figure 15: Modeled and empirical data for High DS condition 
 
 
Model Verification and Validation 
Because the data was not categorical, a correlation of coefficients rather than a Pearson’s 
Goodness of Fit Test was used to assess the error between the expected and empirical 
data, with a target of R
2
 = 0.9.  The reported R
2
 value was much lower, at 0.39.  
However, statistically, significance was also evaluated and despite the low correlation of 
coefficients, there was statistical significance in the model’s output (p = 0.033).  This 
verifies that the model statistically projects trending behavior, but not with applicable 
accuracy. 
The model’s performance for low concentrations was poor, rapidly reaching no 
release despite the presence of clinically relevant doses.  As a result, its outputs did not 
validate the model successfully.  Individual correlations are high with statistical 
significance, but this is likely due to the trend being in the right direction of stable to 
declining dose amounts, even if the accuracy is poor. 
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Figure 16: Summary of verification and validation results 
 
 
Model Usability Analysis 
A summary of usability is as follows.  Inputs were simplified to the concentrations of 
initial particle components using the conventional units for the rest of this experiment.  
Because the volume of the gels and release media were held constant, they were not used 
as variables.  Entrapment efficiency was automatically calculated for the series of entered 
concentrations to generate starting conditions for simulation.  The output was a matrix 
summary of daily release concentrations by mass in µg, and a graphical representation of 
the same for rapid analysis.  Figure 17 below is a sample output graph that was generated 
for the empirical conditions. 
 
 
R2 p
Overall 0.39 0.0033
Control 1.00 0.0002
Low [Mg2+] 0.93 0.0241
High [Mg2+] 0.99 0.0007
Low [MH] 0.96 0.0087
High [MH] 0.96 0.0079
High [DS] 0.95 0.0124
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Figure 17: Sample output of daily release profiles of the empirically evaluated initial conditions 
 
 
Potential for Optimization of System By Manipulation of Concentrations  
Looking at the system being studied, in order to effect control by manipulation of starting 
concentrations of particle components, the significance of the differences in drug release 
was tested.  Results of ANOVA stated that there was a significant difference between the 
different release data sets (p < 0.001).  However, without including the burst release from 
day 1, the system still has significant variability between conditions (p = 0.0016).  There 
is potential for optimization, though not without a more accurate model. 
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Discussion 
Summary of Aims 
Aim 1: Determination of the Effect of Controllable Parameters on Minocycline. – Aim 
Met  
Conditions were chosen to bound the problem using high and low concentrations 
surrounding a high entrapment configuration for particle fabrication.  Release of 
replicates performed as expected with the control having a low initial burst and a stable, 
fairly uniform long term release.  The varied conditions each had lower entrapment and 
less particle stability as the saturation of binding of constituents was less complete when 
outside of optimal ratios. [8, 10]  This was consistent with previous work and proposed 
behavior of the system. 
 The most stable release occurred in the conditions with the highest entrapment 
efficiency.  Excess of components resulted in still stable conditions, as extra-saturation 
concentrations were lost over time.  Shortage of components relative to control resulted 
in less MH loading but still strongly bound MH; this would present with a faster initial 
release that trended toward control. 
 This suggests that behavior is a function of both MH release from particles as well 
as the entrapment efficiency that determines the initial amount of free MH.  The system 
does have saturation points, which was confirmed by the burst release initially of the high 
MH loading condition, that lead to a profile similar to that of the control condition. 
 After Day 1 release, the differences between the conditions’ daily release values 
were blunted.  There was low variability in results, consistency with previous results, and 
the release did start faster for less stable particle conditions, as predicted.  High 
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entrapment conditions had low daily release, and high MH loading was rapidly depleted 
until control behavior was approached. 
While the statistical significance of the differences between the conditions after 
Day 1 did not suggest a high potential for dosing modifications, distinct release profiles 
were made of MH as a result of this experiment and related to entrapment. 
 
Aim 2: Application of a Model to Guide Optimization of a Modifiable Drug Delivery. – 
Aim Partially Met 
The proposed model design presents release data as a function of the aforementioned 
traits of the system.  Incorporating empirically derived constants for diffusion and 
particle degradation reaction rate provided specificity to this system to an otherwise 
abstract model.  This model represents the various strengths of the field of biomedical 
engineering scientific and other principles: fundamental sciences (chemistry and physical 
transports), mathematics (linear algebra and differential equations), programming 
(MATLAB), lab techniques (empirical data collection), experimental design (derivation of 
constants), and collaboration (with topic experts in programming, mathematics, and 
chemistry). 
 As the entrapment efficiency was shown to be a function of the initial loading 
conditions, the derived model applies these principles and concepts to the initial 
conditions of particle formation.  Furthermore, as the general form of the model was 
found without calculating specific values as determined by this specific system, it is 
theoretically translatable to any chelation based drug delivery system. 
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However, statistical testing showed that the accuracy of the model lacks the fine 
number and low concentration fidelity necessary for a system that changes with such 
small margins.  While it statistically showed trend behavior of the system overall, it did 
not yield accurate results for specific condition predictions and the correlation of model 
output to empirical data was too poor for practical application for most conditions. 
 Therefore, Aim 3 was partially met by the specific design component of this 
thesis. 
 
Aim 3: Application of a Model to Guide Optimization of a Modifiable Drug Delivery. – 
Aim Not Met 
Optimization of the drug release system overall was unable to be performed with the 
guidance of the prepared model.  However, tuning is still possible, at the expense of more 
time, resources, and manpower, to empirically test all relevant conditions.  This aim was 
to then tune the model to give distinctly different release profiles by manipulating the 
fabrication concentrations.  In order to explore whether or not this was possible, it was 
first important to establish whether or not there were quantitatively distinctly different 
release profiles. 
 ANOVA of the release profiles showed that there was a statistically significant 
difference between the release profiles generated by broad variation of the initial 
concentrations.  However, the overall correlation with the model was poor, despite a 
significant result.  As a result, it was determined that with the method of manipulation 
being explored within this system did not allow for distinctly different enough release 
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profiles that could be characterized by this modeling approach.  As a result, Aim 3 was 
not met within the scope of this study. 
 
Limitations and Potential Next Steps  
Assumptions in Model Development 
For development of this model, some assumptions were made out of theoretical 
convention to allow for solving of the mathematical representation.  Pseudo-steady state 
was assumed, as the rates of particle degradation and drug diffusion were dramatically 
different.  The release media was larger than the hydrogel and the release concentrations 
were low enough that an assumption of infinite sink was reasonable.  The hydrogel was 
presumed stable, therefore the diffusion coefficient would not be time dependent.  The 
particle kinetics was assumed to be first order after qualitative assessment of drug and 
residue release. 
 These assumptions followed convention in the solution of transports related 
problems.  However, in implementing the model, some further assumptions were made to 
simplify the complex formula. 
 
Challenging Assumptions in Model Application 
Those further assumptions in implementing the model can be addressed as sources of 
weakness in accuracy. 
First, due to the differences in magnitude between the rate reactions, it was 
assumed that the particle formation direction could be neglected.  However, the value of 
kfor was not directly determined.  Because the reaction rates could not be determined with 
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the accuracy needed for time periods as short as that of rapid formation and equilibration 
of particle bound and free MH, the rate constants were based on estimations of elapsed 
time rather than exact time.  Accuracy would be improved by more finely determined rate 
constants. 
 Second, it was assumed that DS release did not dramatically change the kinetics 
of the system.  This was not tested further as shifting DS concentrations relative to Mg
2+
 
would have resulted in different binding energies, which would have required model 
complexity beyond the scope of this study.  However, further accuracy could have been 
achieved by a more robust analysis of the effects of DS release on system behavior. 
 Third, reactions were assumed to be first order based on qualitative analysis of 
release as a representation of the degradation of particles.  This was not conclusively 
tested, and if the order of the reaction was different, reaction rate constants would have 
changed.  As this system is not time-resolved by the methods available (particle 
formation occurs near instantaneously), verification of the rate order was not within the 
scope of this study. 
 Fourth, the entrapment efficiency was assumed to be a linear relationship between 
the bounds tested, and the combination of changing variables was assumed to be an 
average.  The actual complexities of the specific effects of shifting concentrations on 
entrapment efficiency was not evaluated.  Furthermore, the assumption applied 
throughout the release; as release changed, it is possible that the stability of the particles 
changed along with the reduced saturation of binding sites.  This assumption was 
challenged and shown to be an oversimplification.  Potentially a four dimensional surface 
map could be crafted from empirical methods and extensive sampling, from which 
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entrapment efficiencies could be drawn as the starting point of modeling.  However this 
complexity was beyond the scope of the methods in this study. 
Fifth, it was assumed that DS and Mg
2+
 acted in unison, as the simulated binding 
strength if this subunit pairing was the strongest.  The concentration of Mg
2+
 was never 
measured during the release process, and movement of the chelator within the system 
remained uncharacterized due to the complexity of the measuring process and time 
constraints.  Further accuracy would have been likely achieved had all three components 
been treated with the same degree of rigor as MH, though this was beyond the scope of 
the current study.  While DS release concentrations were measured, Mg
2+
 measurements 
were not included in the methods. 
 
Future Work in System Optimization 
As modification of initial conditions of particle fabrication in this study was limited to 
changing the concentrations of the components, it is not enough to conclusively say that 
there is no more control available on this system.  It was determined in previous work 
that this chelation and the binding between the units have pH dependency, as the release 
of MH changes; the binding strength between MH and Mg
2+ 
is pH sensitive and 
decreases in acidic conditions. [8]  This has been considered as a potential control for a 
smart release system, but was deemed too complex for the scope of this study. 
 Furthermore, a larger study with more power could be used to calculate effect 
sizes, which could have greater significance in system manipulation guidance than 
correlation. 
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Final Analysis and Closing Remarks  
Design Component 
While Aim 2 was only partially met, it is important to note that the designed model did 
have statistical significance in its weaker correlation with the trending behavior of the 
system.  While there is clear room for improvement, it cannot be disputed that there is 
utility in a simple approach to modeling when characterizing a drug delivery system.  
Using the fundamental skill set of a biomedical engineer in conjunction with general 
engineering design approaches, a formula was developed that characterizes the overall 
behavior of a complex system. 
 Furthermore, this model supports the current understanding of the system, from a 
theoretical perspective.  It represents, if crudely, the empirically supported position that 
particle formation and drug entrapment are dependent on the initial conditions of 
fabrication, and the entrapment efficiency does set the tone for subsequent release.  
Higher entrapment efficiency correlates with the conditions that match suspected 
saturation conditions of binding, and thus also present with the most stable drug release. 
 Aim 3 was also not met, but this was due to the control methods within the scope 
of this study being exhausted, and a lack of fine accuracy within the model.  Future work 
would be needed to further optimize this delivery system, which shows clear promise for 
localized delivery of MH. 
 
Applications 
One of the primary strengths of the approach used in this modeling process was the 
abstract form.  At no point during the generation of the general form were specifics of a 
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MH-DS-Mg
2+
 system used without first characterizing a nonspecific state and then 
applying the unique parameters of the system to it.  Therefore, while chelating drug 
systems are not common, there is obvious potential in their development, and the general 
form of this model, with some advancement, would be equally applicable with only 
minimal empirical input. 
 A second strength of this approach and therefore potential for application, is less 
specific to the general form and more a product of the development process.  This was a 
complex system beyond the expertise of a single specialist that was modeled by breaking 
the different influences down to basic parts and using a minimal collaborative effort 
where needed.  Such an approach provides affirmation of theoretical mechanisms, 
improved understanding of system behavior, and repeatability of results once the model 
has the necessary robustness.  This was achieved by an understanding of what the 
influences on system behavior were, and by appropriately assuming where they could be 
treated as distinctly independent or where they interfaced with one another.  While the 
form of the system may change, the approach itself has utility in the general effort of 
modeling a drug delivery vehicle. 
 
Conclusion 
Characterization of this system by use of a design process to generate a model stands as 
validation of the skill set of a biomedical engineer.  The system does have potential for 
the chosen application, though the control mechanisms that would be necessary for this 
would likely go beyond altering the ratios of fabrication components.  However, this 
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experiment shows the behavior trend of a system that is biologically safe and potentially 
an effective approach for future treatment of SCI. 
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Appendix 
 
Solutions 
 
 
Table 7: Hank’s Buffered Saline Solution formulation 
 
 
 
 
Equipment and Materials  
 
 
Table 8: Equipment 
Equipment Use 
Eppendorf Research 
Plus Pipettes Accurate volume transfer 
Beckman Coulter 
Microfuge 22R 
Centrifuge 
Separation of particles from 
solution 
Tecan Infinite 200 
NanoQuant 
Spectrometer for 
concentration measurements 
Zetasizer Nano ZS90 
Particle size and 
characteristics 
 
 
 
Table 9: Materials 
Material Source and Model Number 
Minocycline 
Hydrochloride Sigma Aldrich: M9511 
Dextran Sulfate Sigma Aldrich: D8906 
Magnesium Chloride Sigma Aldrich: M9272 
Agarose (SeaPlaque) Loza: 50101 
  
Adjust pH to 7.1-7.4 after dissolving
mg/L mg/mL
CaCl2 140 0.14
KCl 400 0.4
KH2PO4 60 0.06
MgSO4*7H2O 200 0.2
NaCl 8000 8
Na2HPO4*7H2O 90.07 0.09007
NaHCO3 350 0.35
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